We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock

Delisted

FNCH was delisted on the 24th of May, 2024.

45 hedge funds and large institutions have $77.2M invested in Finch Therapeutics Group, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

25% more funds holding

Funds holding: 3645 (+9)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

29% less capital invested

Capital invested by funds: $109M → $77.2M (-$31.7M)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

Holders
45
Holders Change
+9
Holders Change %
+25%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
7
Reduced
10
Closed
15
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
MWNA
51
Marshall Wace North America
New York
-$753K -1,578 Closed
Alyeska Investment Group
52
Alyeska Investment Group
Illinois
-$641K -1,323 Closed
Squarepoint
53
Squarepoint
New York
-$485K -1,000 Closed
CCM
54
CAAS Capital Management
New York
-$323K -667 Closed
Norges Bank
55
Norges Bank
Norway
-$318K -667 Closed
Wellington Management Group
56
Wellington Management Group
Massachusetts
-$293K -614 Closed
Tudor Investment Corp
57
Tudor Investment Corp
Connecticut
-$279K -575 Closed
PHK
58
Point72 Hong Kong
Hong Kong
-$239K -494 Closed
MS
59
Maven Securities
Jersey
-$185K -395 Closed
Point72 Asset Management
60
Point72 Asset Management
Connecticut
-$23K -48 Closed

FNCH Hedge Fund Activity: Q2 2021 in Review

45 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2021, worth a combined $77.2M — down 29% from $109M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new FNCH positions and 15 closed out — a net gain of 9 holders — while 7 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $3.19M. The largest seller was Bank of America, cutting an estimated $10.3M.

  • 45 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2021, up from 36 in Q1 2021.
  • Funds reported $77.2M of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2021, down 29% quarter-over-quarter.
  • 24 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2021 and 15 closed out, a net change of +9 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $3.19M added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2021 was Bank of America, an estimated $10.3M sold.

Based on aggregated 13F filings for Q2 2021.